Cost of Major Surgery in the Sarcopenic Patient

摘要: Background Sarcopenia is associated with poor outcomes after major surgery. There are currently no data regarding the financial implications of providing care for these high-risk patients. Study Design We identified 1,593 patients within Michigan Surgical Quality Collaborative (MSQC) who underwent elective general or vascular surgery at a single institution between 2006 and 2011. Patient sarcopenia, determined by lean psoas area (LPA), was derived from preoperative CT scans using validated analytic morphomic methods. Financial including hospital revenue direct costs were acquired each patient through hospital's finance department. adjusted procedural factors multiple linear regression methods, Mann-Whitney U test used significance testing. Results After controlling factors, decreasing LPA independently increasing payer ($6,989.17 per 1,000 mm 2 LPA, p decrease in (p Conclusions high negative margins Although postoperative complications universally expensive to payers providers, sarcopenic represent uniquely costly demographic. Given that sarcopenia may be remediable, efforts attenuate should focus on targeted interventions optimize risk